NCI to Fund Biomarker Studies for Hematopoietic Malignancies | GenomeWeb

NEW YORK (GenomeWeb News) – The National Cancer Institute plans to fund research that will use a range of 'omics technologies to develop and validate biomarkers for malignancies of the blood under two new grant programs.

NCI will use five-year R01 and two-year R21 grant mechanisms to support scientists developing genomic, proteomic, epigenomic, and transcriptomic delivery and development methods, as well as the use of standardized biospecimens for validation studies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.